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Multi-omics approaches use a diversity of high-throughput technologies to profile the 
different molecular layers of living cells. Ideally, the integration of this information should 
result in comprehensive systems models of cellular physiology and regulation. However, 
most multi-omics projects still include a limited number of molecular assays and there have 
been very few multi-omic studies that evaluate dynamic processes such as cellular growth, 
development and adaptation. Hence, we lack formal analysis methods and comprehensive 
multi-omics datasets that can be leveraged to develop true multi-layered models for 
dynamic cellular systems. Here we present the Stategra multi-omics dataset that combines 
measurements from up to 10 different omics technologies applied to the same biological 
system, namely the well-studied mouse pre-B-cell differentiation. STATegra includes 
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high-throughput measurements of chromatin structure, gene expression, proteomics and 
metabolomics, and it is complemented with single-cell data. to our knowledge, the Stategra 
collection is the most diverse multi-omics dataset describing a dynamic biological system.
Background and Summary
The concept of multi-omics and data-integration has been increasingly used during the last 5 years to describe 
the multitude of high-throughput molecular technologies that can be applied to the study and analysis of bio-
logical systems1. Such techniques hold the promise to uncover the different biological processes and layers of 
regulatory complexity within biological systems. In brief, high-throughput molecular methods can extract infor-
mation of essentially three basic, yet different components of living cells. Nucleic acids can readily be profiled 
using massive, parallel sequencing, which in turn provide deep a characterization of chromatin properties (i.e. 
Hi-2C, ATAC-seq3, DNase-seq4, ChIP-seq5, WGBS6, RRBS7) and the dynamics of gene expression (i.e. RNA-seq8, 
microRNA-seq9,10, PAR-CLiP11, iCLIP-seq12). Proteins are measured by proteomics and phosphoproteomics 
approaches, based on Liquid Chromatography (LC) and Isotope-coded affinity tag labeling (iTRAQ) coupled 
to Mass Spectrometry (MS). Finally, the metabolome and lipidome, i.e. organic compounds, are captured using 
mature techniques such as LC/GC-MS or Nuclear Magnetic Resonance (NMR). Increasingly, multi-omics tech-
nologies are applied during the same physiological conditions from either the same or different samples to gen-
erate a comprehensive set of data spanning multiple molecular levels. The general expectation of multi-omics 
projects is that the combination of multi-layered data will reveal aspects of the complexity of biological systems 
that cannot be fully understood using only a particular data-type. Moreover, in addition to the exciting techni-
cal reality of being able to monitor several complementary data-types, the community has come to realize the 
power of using time in the experimental design. Hence, by collecting data over time, where as a rule the different 
molecular entities are correlated, it is much more amenable to extract key processes from each data-type as well 
as uncovering dependencies between different regulatory layers. These technical and conceptual advances are 
currently being transferred into the vibrant single-cell biology community. Thus, recent advances in single-cell 
omics technologies have made it feasible to perform multi-omics profiling of individual cells. Consequently, 
the single-cell community can benefit from the experiences and lessons derived from time-dependent bulk 
multi-omics analysis. Clearly, a high-resolution single-cell analysis has proven crucial to assess tissue heterogene-
ity13–15, cell fate16,17. In conclusion, we are most likely entering an era where we can target regulatory networks in 
single cells18 using a temporal paradigm coupled to a multi-omics analysis.
While multi-omics projects are frequently depicted as a set of stacked molecular layers that are connected to 
pass information from the genetic component to the organismal phenotype, the harsh reality is that still many 
multi-omics project are constrained by budgetary restrictions and sample limitations which evidently reduce the 
number technologies that can realistically be assessed. In most cases, only a few data types can be included, with a 
limited number of samples, and analyses is as a rule restricted to focus on 2 or 3 regulatory layers. A few interna-
tional projects have however successfully collected large datasets and generated comprehensive portfolios of omics 
measurements. For example, ENCODE19, TCGA20, IHE21, ImmGen22, had the explicit goal to perform an extensive 
characterization of a particular set of cells or tissues. These projects have impacted the scope and type of analysis 
methods and scientific discoveries that can be achieved so far by the multi-omic approach. In some cases combin-
ing multi-level data has the ambition to increase the required statistical power to enable the classification of samples 
or predict disease outcomes. By measuring different types of features the chance of identifying relevant biomarkers 
increases, but the analysis does not automatically lend itself to a mechanistic account of the inter-dependencies 
between these biomarkers as well as their relationship with the outcome, such as a disease. In some cases however, 
two specific omics layers are measured in order to probe their regulatory relationships. For example, methods 
that integrate ATAC-seq or RRBS with RNA-seq might shed light on the epigenetic control of gene expression23, 
while integrating transcriptomics and metabolomics data may help elucidate metabolic regulation24,25. Yet, there 
have been very few multi-omic studies that evaluate dynamic processes such as cellular growth, development and 
adaptation. Hence, we still lack formal analysis methods and comprehensive multi-omics datasets that can be lev-
eraged to develop true multi-layered models for dynamic cellular systems. This state-of-affairs has been the ration-
ale underpinning the formulation of what is referred to as the STATegra project (http://www.stategra.eu/). This 
is a transnational initiative to develop methods, software and data for dynamic multi-omics analyses. From the 
STATegra project several tools for integrative multi-omics data analyses have been published and released26–33.
Here we share the collection of the different STATegra datasets, a multi-omics dataset that combines meas-
urements from up to 10 different omics technologies applied to the same biological system. STATegra uses a 
well-studied system, namely mouse pre-B-cell differentiation, in a cell line model34. This is a highly reproducible 
in vitro system33–36 that allows the generation of sufficient material to deploy a comprehensive set of omics meas-
urements. STATegra covers the three types of biomolecules and the different layers that comprise the basic flow of 
genetic information: chromatin structure (through DNase-seq, RRBS and ChIP-seq), gene expression (RNA-seq 
and miRNA-seq), proteomics and metabolomics. The collection is complemented with single-cell RNA-seq and 
ATAC-seq data on the differentiating conditions. The STATegra multi-omics dataset is unique in the number and 
diversity of omics technologies available and in the dynamic nature of the system. Our ambition has been to gen-
erate this collection of data to serve – in full or using parts of it- as workbench for the development of integrative 
analysis methods for the multi-layered systems biology.
In previous studies, ChIP-seq data from this collection have been used to identify Ikaros targets34. ChIP-seq, 
DNase-seq, RNA-seq and scRNA-seq datasets were used in Vidal et al.35 to describe the cross-talk between 
IKAROS Foxo1 and Myc transcription factors in regulating B-cell development. scATAC-seq, scRNA-seq and 
ATAC-seq data have been used to develop new statistical methods for the integration of single-cell multi-omics33.
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Methods
Experimental design. Figure 1 illustrates the STATegra dataset. The mouse B3 cell line models the pre-BI 
(or Hardy fraction C’) stage. Upon nuclear translocation of the Ikaros transcription factor these cells progress to 
the pre-BII (or Hardy fraction D) stage, where B cell progenitors undergo growth arrest and differentiation34,37. 
The B3 cell line was retrovirally transduced with a vector encoding an Ikaros-REt2 fusion protein, which allows 
control of nuclear levels of Ikaros upon exposure to the drug Tamoxifen34. In parallel, cells were transfected with 
an empty vector to serve as control for the Tamoxifen effect. After drug treatment, cultures were harvested at 
0 h, 2 h, 6 h, 12 h, 18 h and 24 hs (Fig. 1a) and profiled by several omics technologies: long messenger RNA-seq 
(mRNA-seq) and micro RNA-seq (miRNA-seq) to measure gene expression; reduced representation by bisulfite 
sequencing (RRBS) to measure DNA methylation; DNase-seq to measure chromatin accessibility as DNaseI 
Hypersensitive Sites (DHS) and transcription factor footprints, shotgun proteomics and targeted metabolomics 
of primary carbon and amino-acid metabolism. Moreover, single-cell RNA-seq (scRNA-seq) data for the entire 
time-series, while bulk ATAC-seq (ATAC-seq) and single-cell ATAC-seq (scATAC-seq) were obtained in a later 
round of experiments for 0 h and 24 h-time points of Ikaros induction only (no control series were run for these 
datasets). The dataset is complemented by existing ChIP-seq data on the same system equivalent to our 0 h and 
24 h time points34. In total, 793 different samples across the different omics datasets define the STATegra data 
collection (Fig. 1b).
The time points analyzed were based on previous microarray studies34 and have been fully validated by com-
paring the transcriptional response in this experimental system to pre-B cell differentiation in vivo. Ikaros trans-
locates to the nucleus of B3 cells within minutes, binds to target promoters and changes RNAP2 occupancy 
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Fig. 1 STATegra data generation. (a) Inducible Ikaros B3 cell system. Time course experiment collects samples 
at 6 time-points after Tamoxifen induction of Ikaros expression, Control cells carry empty vector. (b) Diversity 
of omics platforms, number of biological replicates, batch distribution and lab assignment for B3 cell culture 
and omic library preparation. Data on each row corresponds to the one omics type on the left. +Previous data 
from34.
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in primary transcript levels36 and was chosen because the data presented here were generated by conventional 
RNA-seq, which relies on changes in steady state, rather than primary transcript levels.
Culture conditions. B3 cells containing inducible Ikaros can be expanded before induction of Ikaros to pro-
duce sufficient material for all omics experiments. G1 arrest occurs within 16 h following Ikaros induction. Cells 
containing inducible Ikaros were generated by transducing mouse pre-B cell line B3 with mouse stem cell virus 
(MSCV) retroviral vectors encoding a fusion protein of haemagglutinin-tagged wild type Ikaros (HA-Ikaros) and 
the estrogen receptor hormone-binding domain (ERt2), followed by an internal ribosomal entry site (IRES) and 
GFP. Control cells were generated by transducing mouse pre-B cell line B3 with mouse stem cell virus (MSCV) 
retroviral vectors encoding the estrogen receptor hormone-binding domain (ERt2) followed by an internal ribo-
somal entry site (IRES) and GFP. Retroviral infected B3 cells were sorted based on GFP levels. GFP positive cells 
were expanded in culture for few days (3–4) and then frozen. Frozen vials containing 5 million cells were stored 
in liquid nitrogen.
For time course experiments, 10 million control and Ikaros cells were thawed and expanded for 4 days. Four 
days later cells were plated for induction of the different time points. Both control and Ikaros cells were split in 
flasks containing 20 million cells at a density of 0.5 million cells per ml each. For time point inductions, 0.5 uM 
4-hydroxy-tamoxifen (4-OHT) was added to both, a flask containing Ikaros cells and a flask containing control 
cells, at one of the specified times: 2 h, 6 h, 12 h, 18 h or 24 h before collection. Cells for time point 0 h (no 4-OHT) 
induction were obtained separately in three different batches (Fig. 1b). All cells within the same experimental 
batch were harvested simultaneously. Cells were centrifuged for 5 min at 1200 rpm, washed twice in PBS and 
counted to aliquot. Aliquots of 10 million cells were done for RNA-seq and metabolomics and proteomics plat-
forms and of 5 million cells for miRNA-seq and Methyl-seq platforms. Cell pellets were snap-frozen in liquid 
nitrogen and stored at -80. 20–25 million and 50,000 cells were used for DNase-seq and bulk ATAC-seq samples. 
The full time course experiment was repeated different times (batches) to generate biological replicates (Fig. 1b). 
The same physical cultures were used to obtain cells for mRNA-seq, miRNA-seq, RRBS and proteomics. Other 
omics technologies ran their own cultures to obtain cell material.
acquisition of Multi-omics data. RNA-seq. Total RNA was isolated with RNAbee (Ambion), frozen ICL 
and transported via courier (<1 day) to Karolinska Institutet. To account for the impact of the different sources 
of variability during RNA-seq profiling, we implemented a carefully balanced distribution of samples in relation 
to time points (6 time points), treatment (Ikaros vs Control), library preparation, bar-code, sequencing run and 
lanes and biological replicates (3 batches). Briefly, samples were first balanced in six library preparation runs of 
6 samples each (Fig. 2). Secondly, each RNA-seq library was split into two (total of 72) in order to better account 
for variability associated with sequencing. Finally, for sequencing, 75 nucleotides paired-end, the 72 libraries were 
balanced into 4 flow-cells and in each lane we included 3 libraries. In each lane, we ensured to have different 
libraries, different batches, different time points and at least both conditions present. Additionally, we balanced the 
time-points, conditions and batches within each flow-cell. For each flow-cell, a full lane was reserved for quality 
control. We aimed to obtain 50 M reads per library, therefore 100 M reads per sample. Libraries were built using 
the strand-specific RNA-seq dUTP protocol38. Sequencing was conducted on an Illumina HiSeq 2500 platform.
Small RNa-seq for miRNa analysis. Small RNA-seq analysis was performed using Trizol-extracted total 






































LANE 1 LANE 2 LANE 3 LANE 4


































12 24 2 24 18
2 18 0 24 12
0 2 12 18 24
12 6 2 18 0

































































































Fig. 2 Experimental design for RNA-seq.
5Scientific Data |           (2019) 6:256  | https://doi.org/10.1038/s41597-019-0202-7
www.nature.com/scientificdatawww.nature.com/scientificdata/
6 h, 12 h, 18 h and 24 h. RNA quality was assessed using Bioanalyzer (Agilent Technologies) evaluating the RNA 
integrity number (RIN). The library was generated using TruSeq Small RNA Sample Preparation Kit and deep 
sequencing was performed in Illumina Hiseq 2000 platform. Between 15 and 20 millions of sequencing reads 
were obtained from each sample.
The library preparation and sequencing of the biological replicates were conducted in two different occasions 
(technical batches). Figure 3 shows the experimental design according to the batch in which samples were pro-
cessed. There were two experimental conditions (C = Control, IK = Ikaros) and the 3 biological replicates per 
condition and time point were numbered as 1, 2 and 3. For some of these biological replicates one additional 
technical replicate was generated (Fig. 3) in order to estimate the variability between technical batches and to 
correct any potential batch effect.
DNase-seq. DNase-seq was performed on ~20–25 million cells with 3 biological replicates for all time-points 
(0–24 hours) and conditions (Ikaros-inducible and control). Briefly, cells were harvested and washed with cold 
1X PBS, prior to nuclei lysis. Lysing conditions were optimized to ensure >90% recovery of intact nuclei. DNaseI 
concentrations were titrated on Ikaros-inducible and control cells using qPCR against known positive DNaseI 
hypersensitive promoters (Ap2a1, Ikzf1, Igll1) and negative inaccessible hypersensitive promoters (Myog, Myod) 
in our biological system, thereby reducing excessive digestion of DNA. Enrichment of DNaseI hypersensitive 
fragments (0–500 bp) was performed using a low-melt gel size selection protocol. Library preparation was per-
formed and sequenced as 43 bp paired-end NextSeq 500 Illumina reads. DNaseI libraries were sequenced at 
a minimum depth of 20 million reads per each biological replicate. To perform DNaseI footprinting analysis, 
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Fig. 3 Experimental design for small RNA-seq. Two sequencing batches were run. Samples with red filling were 
repeated at both batches to allow for estimation of batch effects.
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RRBS. Genomic DNA was isolated using the high salt method and used for reduced representation bisulfite 
sequencing (RRBS), a bisulfite-based protocol that enriches CG-rich parts of the genome, thereby reducing the 
amount of sequencing required while capturing the majority of promoters and other relevant genomic regions. 
This approach provides both single-nucleotide resolution and quantitative DNA methylation measurements. In 
brief, genomic DNA is digested using the methylation-insensitive restriction enzyme MspI in order to generate 
short fragments that contain CpG dinucleotides at the ends. After end-repair, A-tailing and ligation to methylated 
Illumina adapters, the CpG-rich DNA fragments (40–220 bp) are size selected, subjected to bisulfite conversion, 
PCR amplified and then sequenced on an Illumina HiSeq 2500 PE 2 × 100 bp39. The libraries were prepared for 
100-bp paired-end sequencing. Around 30 million sequencing reads were obtained from each sample.
Single-cell RNa-seq. Single cells were isolated using the Fluidigm C1 System. Single-cell C1 runs were 
completed using the smallest IFC (5–10 um) based on the estimated size of B3 cells. Briefly, cells were collected for 
each time-point at a concentration of 400 cells/μl in a total of 50 μl. To optimize cell capture rates on the C1, buoy-
ancy estimates were optimized prior to each run. Our C1 single-cell capture efficiency was ~75–90% across 8 C1 
runs. Each individual C1 capture site was visually inspected to ensure single-cell capture and cell viability. After 
visualization, the IFC was loaded with Clontech SMARTer kit lysis, RT, and PCR amplification reagents. After 
harvesting, cDNA was normalized across all libraries from 0.1–0.3 ng/μl and libraries were constructed using 
Illumina’s Nextera XT library prep kit per Fluidigm’s protocol. Constructed libraries were multiplexed and puri-
fied using AMPure beads. The final multiplexed single-cell library was analyzed on an Agilent 2100 Bioanalyzer 
for fragment distribution and quantified using Kapa Biosystem’s universal library quantification kit. The library 
was normalized to 2 nM and sequenced as 75 bp paired-end dual-indexed reads using Illumina’s NextSeq 500 
system at a depth of ~1.0–2.0 million reads per library. Each Ikaros time-point was performed once, with the 
exception of 18 and 24 hour time-points, in which two C1 runs were required in order to achieve approximately 
~50 single-cells per each time-point.
Bulk and single-cell ataC-seq. Single-cell ATAC-seq was performed using the Fluidigm C1 system as 
done previously40. Briefly, cells were collected for 0 and 24-hours post-treatment with tamoxifen, at a concentra-
tion of 500 cells/μl in a total of 30–50 μl. Additionally, 3 biological replicates of ~50,000 cells were collected for 
each measured time-point to generate bulk ATAC-seq measurements. Bulk ATAC-seq was performed as previ-
ously described3. ATAC-seq peak calling was performed using bulk ATAC-seq samples. ATAC-seq peaks were 
then used to estimate the single-cell ATAC-seq signal. Our C1 single-cell capture efficiency was ~70–80% for our 
pre-B system. Each individual C1 capture site was visually inspected to ensure single-cell capture. In brief, ampli-
fied transposed DNA was collected from all captured single-cells and dual-indexing library preparation was per-
formed. After PCR amplification of single-cell libraries, all subsequent libraries were pooled and purified using a 
single MinElute PCR purification (Qiagen). The pooled library was run on a Bioanalyzer and normalized using 
Kappa library quantification kit prior to sequencing. A single pooled library was sequenced as 40 bp paired-end 
dual-indexed reads using the high-output (75 cycle) kit on the NextSeq 500 from Illumina. Two C1 runs were 
performed for 0 and 24-hour single-cell ATAC-seq experiments.
Proteomics. A heavy-isotope labeled cell line representing the preB3 cell line at the starting condition was 
spiked to the sample before trypsin digestion to balance differences in sample amount resulting from sample 
preparation. After tryptic digestion, proteomic measurements of the 36 biological batches were analyzed by 
one-dimensional nanoRP-C18 LC-MS/MS in technical triplicates on an LTQ Orbitrap platform coupled to 
an Ultimate 300 RSLC system (Thermo-Fisher). First, peptide mixtures were desalted on a trapping column 
(0.3 × 5 mm, Acclaim PepMap C18, 5 µm, Thermo-Fisher) at a flow rate of 25 µl/min of 0.05% TFA. A linear gra-
dient from 3% B to 32% acetonitrile in 0.1% formic acid in 4 h was applied optimal separation of the complete pro-
teome sample. Peptides eluting from the column were directly transferred to the gas phase via a nano-electrospray 
ionization source (Proxeon) and detected in the mass spectrometer. A data-dependent acquisition cycle consist-
ing of 1 survey scan at a resolution of 60,000 and up to 7 MS/MS scans were employed. Orbitrap MS spectra were 
internally calibrated on the siloxane signal at 442.1 m/z Charge-state detection was enabled allowing for a precur-
sor selection of charges 2–5 and excluding precursors with undefined, single and higher charge. Precursors with 
minimal signal intensity of 5000 cps, were isolated within a 1.2 Da window and fragmented by CID (normalized 
collision energy 35, activation time 30 ms, Q 0.25) and analyzed in the ion trap. Previously analyzed precursors 
were dynamically excluded from MS/MS selection for 180 seconds.
Metabolomics. Metabolomics measurements were performed on different biological batches than the other 
omics platforms because the sample preparation part for metabolomics is different than for the rest. In particular, 
metabolomics requires acute stopping of all metabolic reactions after sampling, while for other types of measure-
ments this is not so critical. The cell extraction protocol for metabolomics consisted of filtration, washing, and 
quenching steps to remove medium from the cells and stop metabolism. Four biological batches (9, 10, 11 and 
12) were acquired. Visual inspection of the cell pellets showed that batch 11 and 12 contained samples that were 
not completely dry. The metabolomics measurements were obtained with two different analytical platforms, a 
targeted liquid chromatography mass spectrometry (LC-MS) platform and gas chromatography mass spectrom-
etry (GC-MS) platform. The LC-MS is a targeted platform measuring amino acids and biogenic amines and the 
GC-MS focuses on polar metabolites of the primary metabolism such as glycolysis, cyclic acid cycle and amino 
acid metabolism. LC-MS and GC-MS data had measurements for respectively 36 and 40 metabolites. The meas-
urements were done on exactly the same samples. 80% of the pooled extract was for GC-MS, 10% for LC-MS, 
8% for protein weight. Some metabolites were measured at both platforms. In that case, the LC-MS value was 
selected.
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The metabolomics measurement pipeline includes two types of control: the quality control (QC) sample and 
the internal standard solution. The QC sample is typically a mixture of study samples that is inserted after each six 
study samples in the measurement series and is used to correct for experimental drift of the analytical instrument. 
Because of the limited availability of sample material the QC sample used here was not a mixture of study samples 
but material of control B3 cells not activated with tamoxifen. The internal standard solution for the GC-MS and 
LC-MS consists of 13C labeled yeast extract, which is added to each study sample at the beginning of the sample 
preparation process to correct for experimental errors made during the sample processing. For LC-MS an addi-
tional internal standard solution is added consisting of 13C labeled amines for most of the amines measured with 
the platform. For LC-MS the labeled versions of the metabolites were used as internal standard while for GC-MS 
the best internal standard was chosen based on the smallest residual standard deviation of the QC samples. 
During the process of measurement, the time points for each batch were randomized, but each Ikaros sample and 
its control were maintained together.
omics pre-processing. Data pre-processing is next described in detail for each omics type. Figure 4 shows 
a comparative overview of the different preprocessing pipelines.
RNa-seq. Tophat241 was used to map fragments to the mm10 reference genome; the very-sensitive mode 
only allowing a unique best mapping per fragment was used. Picard (https://broadinstitute.github.io/picard/) 
and Fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) were used to perform a quality control 
considering elements such as duplication levels, GC content and k-mer overrepresentation. We observed that 
the duplication level was high (over 90%) in most samples as expected for high sequencing-depth in RNA-seq; 
additionally, some samples were having a GC content over-representation (Supplementary file S1). Trimming 
was applied to remove Illumina primers and low-quality nucleotides42. HTSEQ43 intersection-option was used to 
assign fragments to genes. Data were normalized using cqn44, which corrects for GC content and gene-length. A 
non-parametric version of Combat methodology45 was used after cqn to correct for library-preparation effects.
miRNa-seq. The quality of the sequencing reads was checked with the Fastqc tool with good results 
(Supplementary file S2). Alignment of raw data was performed using Novoalign (http://novocraft.com/) on 
mouse miRNA sequences from mirBase. Quantification was performed using multiBamCov46 and counts were 
found for 1,086 out of 1,908 miRNAs present in the database. Low count miRNAS were further filtered out with 
the CPM (counts per million) method in NOISeq R package47 by setting a threshold of 1 for CPM. The final data-
set contained 469 miRNAs. GC content bias was eliminated with the cqn R package44, and data was normalized 
by TMM48. PCA analysis indicated that, although Control and Ikaros samples separated well above batches, a 
batch effect was observed for different Ikaros time points (not shown). This bias was corrected by ComBat45 and 
technical replicates were used to avoid confounding batches with experimental conditions. After batch correction, 
technical replicates were averaged for further analyses.
Fig. 4 Preprocessing pipelines for 8 omics technologies. See methods for details.
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DNase-seq. DNase-seq reads were trimmed to 36 bp and paired-end mapped to the mm10 reference genome 
using Bowtie249 with options: –v 2 –k 1 –m 1–best –strata. DNase-seq peaks were called for each replicate using 
the HOMER findPeaks function. We employed a specific peak-calling strategy to capture several features of our 
DNaseI hypersensitive sites (DHS). Our strategy was to include both ‘narrow’ and ‘broad’ DHS peaks in our 
analysis. This captured a comprehensive set of sites with a wide DHS dynamic range. Initially, we used HOMER 
to determine narrow DHS peaks using a default size parameter (120–150 bp) with a minimum peak distance of 
50 bp between DHS and an FDR of 1%. We then included a second round of peak calling, restricting to a peak size 
of 500 bp with a minimum peak distance of 50 bp between DHS peaks and an FDR of 1%. We then merged the 
two peak sets for each replicate. We required a minimum 1 bp overlap of peaks across all three biological repli-
cates for each time-point respectively and generated a consensus DHS peak list across all time-points.
The consensus DHS (53,624) were filtered for chrM peaks, partial chromosomes, and mouse ENCODE black-
list regions. Counts representing the chromatin accessibility were estimated for each consensus DHS using the 
Bedtools coverageBed function. Additionally, no DHS were considered with less than 10 reads (~1 RPM) in all 
time-points, resulting in a final dataset with 52,788 consensus DHSs. Data were normalized by a combination of 
RPKM and TMM. An unwanted source of variability was detected in the data that could not be associated with 
any experimental factor such as production batches or library preparation. Therefore, a method like ComBat 
could not be applied in this case but we used the ARSyN method50 instead which can estimate the systematic 
sources of noise and then correct the data to remove them.
RRBS. Initial quality assessment was based on data passing the Illumina Chastity filter. The second quality 
assessment was based on the reads using the Fastqc quality control tool version 0.10.0. Reads were adaptor- 
and quality-trimmed using Trim-Galore Software v0.3.4 (http://www.bioinformatics.babraham.ac.uk/projects/
trim_galore/) in RRBS paired-end mode, in order to decrease methylation call errors arising from poor quality 
data. Mapping to the reference genome (GRCm38, mm10) was performed using Bismark v0.10.151 and Bowtie249. 
The quality of the mapping was inspected using HTSEQ-qa43. SAM files were used as input in Bismark to obtain 
methylation calls. Paired-end mode with no overlap mode was specified. The first four bases from each read were 
avoided to eliminate M-bias, i.e. deviation from the horizontal line in the mean CpG methylation level for each 
read position. BedGraph and *.cov files were further considered and analyzed with the BiSeq package52. Coverage 
was inspected before proceeding to smooth the methylation levels (between 0 and 1) per CpG site. Briefly, we 
firstly defined “frequently covered CpG sites” as those sites that are covered in at least 2/3 of the samples. The 
frequently covered CpG sites were considered only to define the cluster boundaries and we defined CpG clusters 
using a maximum distance of 100 bp and at least 20 CpGs. This selection resulted in 1,116,417 CpG sites within 
CpG clusters, with no threshold on coverage. The extra coverage of unusually high covered sites (95% quantile 
of the coverage) was eliminated to remove potential biases during the smoothing step introduced by CpGs with 
exceptional high coverage. Then, the methylation levels were smoothed with a bandwidth of 80 bp as described52. 
Clustering analysis was performed with the methylation estimates of the 20% most variable positions (based on 
CV), with multidimensional scaling or hierarchical clustering. M-values were obtained after thresholding meth-
ylation levels in the interval [0.01, 0.99] to avoid infinite values, as M = log2(b/(1-b)), where b is the constrained 
methylation level. The final dataset contained a total of 1,116,417 Methylation features.
Single-cell RNa-seq. A total of 560 single-cell RNA-seq libraries were mapped with Tophat53 to the mouse 
Ensembl gene annotations and mm10 reference genome. Single-cell libraries with a mapping rate less than 50% 
and less than 450,000 mapped reads were excluded from any downstream analysis, resulting in 324 single-cells for 
all subsequent analysis. Cufflinks54 version 2.2.1 was used to quantify expression from single-cell libraries using 
Cuffquant. Gene expression measurements for each single-cell library were merged and normalized into a single 
data matrix using Cuffnorm. Genes with zero counts in more than 80% of the samples were removed resulting in 
a data matrix with 9,075 genes.
ataC-seq. Single-cell libraries were mapped with Bowtie49 to the mm10 reference genome using the follow-
ing parameters (bowtie -S -p 2–trim3 10 -X 2000). Duplicate fragments were removed using Picard (http://picard.
sourceforge.net). We considered single-cell libraries that recovered >5k fragments after mapping and duplication 
removal. Bulk ATAC-seq replicates were mapped to the mm10 reference genome using the following parameters 
(bowtie2 -S -p 10–trim3 10 -X 2000). Peak calling was performed on bulk replicates using HOMER with the 
following parameters (findPeaks <tags> -o <output> -localSize 50000 - size 150 -minDist 50 –fragLength 0). 
The intersection of peaks in three biological replicates was performed. A consolidated list of 25,466 peaks was 
generated from the union of peaks from 0 and 24 hour time-points.
Proteomics. Data were searched against a protein sequence database containing all confirmed mouse protein 
sequences from the Uniprot database (swissprot), common contaminants and reversed using the Andromeda 
algorithm within the MaxQuant software suite version 1.5.0.0. Mass deviation settings for peptide detection were 
20 ppm for the first search and 7 ppm for the main search. IT MS/MS data were searched with a mass accuracy 
of 0.6 Da. N-terminal acetylation and methionine oxidation were set as variable modifications, carbamidometh-
ylation of cysteine as fixed modification. Unidentified signals, present at a similar retention environment, were 
matched if at least one run had a positive identification of the peptide sequence by enabling the match between 
run option within an alignment time window of 30 min. Obtained search results were filtered for reversed data-
base hits on the peptide spectrum match level (1%) and the protein level (2%) and all protein groups with at least 
1 razor or unique peptide were initially accepted. For quantitation of proteins over the different timepoints, light 
protein intensities were extracted from the data file for each protein.
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Distant measuring intervals and long gradient times lead to a substantial variation between peak localization 
and areas of individual LC-MS/MS runs resulting in a huge number of missing values. This issue was addressed by:
 (a) Alternative LC MS/MS alignment routines. Upon the observation that missing values were not random-
ly distributed, but associated to particular samples, we believed that a misalignment of chromatograms 
played a role. We improved the alignment between samples to rescue some of the missing values.
 (b) RNA-seq data was used as database source protein identification. The rationale is that the mRNAs of 
expressed proteins should be found within the RNA-seq detected genes. Reducing the size of the protein 
database to proteins detected by RNA-seq will reduce the number of false hits and lead therefore to more 
specific data on the pre-B cell proteome. Since proteomic data exhibit a lower coverage of the proteins 
abundant in a cell, a substantial data loss is not expected.
 (c) A conservative missing value imputation strategy was applied to log2-transformed data corresponding to 
2,527 proteins. Briefly, this strategy discarded proteins with a large number of missing values, considered 
as not expressed those proteins that were missing either in the whole Control or Ikaros condition, and im-
puted values in conditions with only 1 out of 3 missings. Samples were normalized by the mean of medians 
per experimental condition. Proteins with missing values in all the 3 replicates per condition in at least 
11 of the 12 conditions were discarded, resulting in 2,396 proteins used for the imputation. Proteins with 
all missing values in the Control condition were imputed from a Gaussian distribution with mean 50% of 
the minimum sample value and with standard deviation equal to the median of all within-group standard 
deviations for all the proteins in the original data. The same procedure was followed for Ikaros condition. 
Finally, when for a given condition only one of the three biological replicates was missing, the missing 
value was computed as before but using the mean of the two measured values. The resulting imputed data 
with no missing values were normalized by TMM. Both imputed and non-imputed datasets are available at 
the STATegra Figshare repository.
Metabolomics. For the GC platform, a 13C labeled yeast extract was added as internal standard. A Quality 
Control (QC) sample was measured every 6 samples (See QC data in Supplementary file S3). For each of the 
compounds measured on the GC platform, the labeled compound peak that led to the smallest standard error in 
the QC samples for that compound, was selected as internal standard. Because the amount of sample was almost 
completely used for the two analytical platforms no replicate analyses were possible. This meant that the internal 
standard selection could not be validated using replicated samples as is common practice. For the targeted LCMS 
method, the optimal internal standards for each metabolite were chosen during optimization and validation of 
the method. The limited within batch drift effects were corrected using the batch correction approach developed 
by van der Kloet et al.55.
Four biological batches (batches 9 through 12) were provided to the metabolomics platforms, which were 
(physically) different from the batches used for mRNA-seq, miRNA-seq and proteomics. Visual inspection 
showed that samples of batch 11 and 12 were not completely dry. Analysis of some key metabolites and PCA 
showed batch 12 levels to be outside the general trend in batches 9, 10 and 11 (not shown). Therefore, it was 
decided to exclude batch 12 from further analysis.
Both analytical platforms show some overlap in the metabolites that were measured. On GCMS 22 metabolites 
were uniquely quantified and 18 metabolites were quantified uniquely on LCMS, while 18 metabolites were quan-
tified both on GCMS and LCMS, making a total of 58 metabolites. Although the intensity levels of the GCMS and 
LCMS were rather different a high correlation between the two platforms for most overlapping metabolites was 
observed. Metabolite levels were log scaled and levels were mean-centered over the three batches 9, 10 and 11. For 
the metabolites that were measured both on GCMS and LCMS, the LCMS values were selected as this platform is 
targeted for these types of metabolites.
Data Records
Raw data. STATegra multi-omics data have been deposited in different public repositories dedicated to dif-
ferent data types56–64. Table 1 shows a list of the current hosting of raw data files. Moreover, pre-processed data 
arranged as a data-matrix per omics data-type have also made available at Lifebit65 site and at Figshare66.











Table 1. Public repositories hosting STATegra multi-omics data.
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Stategra Knowledge Base. In order to evaluate how to best integrate and semantically map specific prior 
knowledge and relevant information derived from multiple sources together with heterogeneous experimental 
data, a STATegra Knowledge network for B-cell differentiation (KB) was developed67 applying the BioXMTM 
knowledge management environment68. Prior knowledge includes among others relevant molecular elements 
(genes, proteins, metabolites, etc.), functional information (GO, OMIM, etc.), functional interactions (e.g. 
protein-protein interaction, transcriptional regulation (e.g. mouse TF-regulatory network), miRNA network, 
etc.) and information about gene homologs (mouse, rat, human). Also, genome features with coordinates for 
peak-to-gene associations of NGS data (e.g. mouse genome assembly mm10), metabolic and signal transduction 
pathways, cell types related to B-cell differentiation as well as ontologies such as the mouse anatomy ontology 
(MGI) were incorporated. This integrated and dynamically organized knowledge serves as information rich, struc-
tured background network. Semantic mapping of experimental data to this background network of prior knowl-
edge enables complex integration and analysis approaches69. The STATegra Knowledge Base visualizes multiple 
Fig. 5 Biomarkers of B3 cell differentiation across three experimental batches.
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omics data types and summarizes information from different layers on top of a network graph. The overlay of 
experimental data on top of such networks helps interpretation of results as well as validate database predictions.
technical Validation
Validation of time course replicability. As a quality control of batch replicability, real time RT-PCR was 
used to check the impact of Ikaros in gene expression upon induction and reproducibility across time course 
experiments. RNA from all samples was extracted using RNAbee (AMS Biotechnology (Europe) Ltd) and treated 
with Turbo DNAse (Life technologies). Bioanalyser technology was used to check the RNA integrity and samples 
were quantified using a Nanodrop. Changes in the expression of few previously identified Ikaros-responsive genes 
were analyzed (Fig. 5). As expected34, early down-regulation of Igll1 and Myc, late down-regulation of Slc7a5, Hk2 
and Ldha, and up-regulation of Foxo1 and Lig4 were consistently observed in the three independently collected 
time course replicates. Either frozen pellets or RNA samples from the time course experiments and 0 h time point 
collections were sent to the different experimental labs to perform the library preparation for the sequencing.
Validation of dataset replicability and co-variation structure. To assess the quality of our data we 
analyzed the correlation values between replicates of the same condition and compared to correlation values 
when samples belonging to different conditions were compared (Fig. 6a). We applied this analysis to RNA-seq, 
miRNA-seq, DNAse-seq, Methyl-seq, proteomics and metabolomics. ChIP-seq and ATAC-seq data were 
excluded as only two replicates were available in each case. Also, single-cell data was excluded from this analysis, 
as the zero-inflated nature of the technologies makes correlation analysis meaningless. We found that, for all 
technologies, biological replicates had very high correlation (>0.9, Fig. 6a), in general higher than the correla-
tions among samples of different experimental conditions that also displayed a wider range of values. This result 
reflects the time course nature of the experimental design, where closer time points have higher correlations than 
distant time points.
Fig. 6 Quality control of STATegra multi-omics data. (a) Distribution of pair-wise correlation values for 
samples belonging to different (Across) or the same (Within) experimental conditions. (b) PCA analysis. Only 
the Ikaros series is shown. Data were preprocessed as described in Methods. Time progression is represented by 
an increasingly darker red color.
1 2Scientific Data |           (2019) 6:256  | https://doi.org/10.1038/s41597-019-0202-7
www.nature.com/scientificdatawww.nature.com/scientificdata/
To further validate data and to understand whether the different omics measurements captured the dynam-
ics of B-cell differentiation and/or had a similar co-variation structure, we ran Principal Component Analysis 
for all datasets (Fig. 6b). In general, the different multi-omics datasets show PCA plots that recapitulate the 
time progression of our inducible system. A well spread temporal progression on the first PC was observed for 
mRNA-seq, miRNA-seq and scRNA-seq data, being RNA-seq the dataset with the most consistent progression 
signal. Metabolomics and Proteomics showed a two-stage pattern, with samples from 0 h–12 h hours clustering 
at negative values, and samples at 18 h–24 h clustering at positive values of the first and second PC, respectively. 
DNase-seq showed a noisier, but distinguishable distribution of the temporal signal at PC2, while RRBS is the 
only dataset with an unclear temporal pattern. For scATAC-seq, only two time points were measured and cells 
nicely separated on the second PC. This analysis reveals that multi-omics datasets consistently described the 
progression of B-cell differentiation but also that the different omics technologies present different noise levels. 
Interestingly, dynamic patterns are slightly different for nucleic acids and proteins and metabolites, possibly indi-
cating a later response of these with respect to the transcriptional change.
Multi-layer data example. In order to illustrate the consistency of the STATegra multi-layer data, we ana-
lyzed values for the lactate dehydrogenase A gene (Fig. 7). LDHA catalyzes pyruvate to lactate conversion in the 
final step of anaerobic glycolysis (Fig. 7a). Ldha is one of known Ikaros target genes34 and downregulated upon 
Ikaros-induced differentiation of the B3 cell line (Fig. 5). The STATegra footprint data confirmed that Ikaros binds 
to the promoter region of the Ldha gene (Fig. 7b) while the promoter DHS signal, mRNA and protein levels were 
Fig. 7 STATegra data for lactate dehydrogenase A. (a) LDHA reaction at glycolysis. (b) Promoter regions of the 
Ldha gene showing a DHS and IKZF1 footprint identified by DNase-seq. Only values for the Ikaros-induced 
time course are shown. In red, the IKZF1 ChIP-seq peak region. (c–e) Paintomics27 representation for Ldha data 
as heatmaps and line plots of log2FC values between Ikaros and Control. Data points correspond, from left to 
right, to 0, 2, 6, 12, 18 and 24 hours after Ikaros induction. At heatmaps, red indicates up-regulation and blue 
indicates down-regulation. (c) Ldha data for DNase-seq, RNA-seq, Proteomics. (d) Data for miRNA-seq where 
miRNA-Ldha target data was predicted by at least 5 algorithms in the mirWalk70 database. (e) STATegra log2FC 
values for pyruvate (left) and lactate (right). (f) Major Gene Expression, Proteomics, and DNase-seq trends for 
glycolysis pathway computed by Paintomics27.
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downregulated as cells progressed towards the pre-BII stage (Fig. 7c). We obtained confirmed microRNAs target-
ing the Ldha transcript 3’UTR from the mirWalk database70 and identified four microRNAs with a strong negative 
correlation with Ldha expression levels (Fig. 7d). One of these microRNAs, mir449a-5p, has been reported to bind 
and regulated Ldha in human cells71. Additionally, in comparison with the control, decreasing levels of pyruvate 
and lactate were found in Ikaros samples as differentiation progressed (Fig. 7e), consistent with a lower LDHA 
enzymatic activity. Finally, STATegra data indicated a general downregulation of glycolysis at gene expression, pro-
tein levels and DNA accessibility (Fig. 7f). In summary, the STATegra data recapitulates known metabolic-switch 
observations in the B3 system and showed a consistent pattern of change across regulatory layers.
Code availability
Preprocessing scripts for each of the omics datasets, together with relevant intermediate files, are available at 
the STATegraData GitHub repository72. Preprocessing scripts collect in one.txt file all code and parameters 
required to transform raw data files into one consolidated data matrix with ready to use quantitative data, where 
samples are arranged in columns and features are arranged in rows. Script files may contain code for multiple 
programming languages or simply list parameters used in commercial software when applicable.
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